A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fruquintinib in Advanced Solid Tumors and Metastatic Colorectal Cancer
Phase of Trial: Phase I
Latest Information Update: 02 Dec 2019
Price : $35 *
At a glance
- Drugs Fruquintinib (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Hutchison MediPharma
- 26 Nov 2019 Number of arms changed form 3 to 4, cohort B added having patients with metastatic colorectal cancer, Trial focus changed from AR to AR and TU. Planned patient number changed form 18 to 15
- 26 Nov 2019 Planned End Date changed from 15 Dec 2019 to 15 Jun 2020.
- 16 Nov 2018 According to a Chi-Med media release, this study is almost complete.